Wegovy on the NHS: NICE TA875, Specialist Services and Access

Wegovy is available on the NHS, but access is narrower than many people expect. For weight management, NICE TA875 recommends semaglutide only within specialist weight management services, for people who meet specific BMI and health criteria, and for a maximum of two years. Since May 2026, NICE TA1152 has also recommended semaglutide to reduce the risk of heart attack and stroke in adults with established cardiovascular disease and a BMI of at least 27. In practice, availability depends heavily on local services and waiting lists. This guide explains the rules, how referral works and what to ask your GP.

How NHS access to a medicine works

In England, a medicine reaches routine NHS use through two separate steps.

1. Licensing. The Medicines and Healthcare products Regulatory Agency (MHRA) decides whether a medicine is safe and effective enough to be authorised, and for which uses. Wegovy was authorised in the UK for weight management in September 2021, and its licence was extended in 2024 to include reducing cardiovascular risk.
2. Appraisal. The National Institute for Health and Care Excellence (NICE) decides whether the NHS should fund it and for whom, based on clinical and cost-effectiveness. When NICE recommends a medicine in a technology appraisal (TA), NHS commissioners in England are normally required to fund it within a set period, often 90 days.

Wales and Northern Ireland usually follow NICE technology appraisals. Scotland has its own body, the Scottish Medicines Consortium (SMC), which makes separate decisions. Arrangements in each nation can differ, so if you live outside England, check with your GP or local health board.

A licence sets the outer boundary of who can be prescribed a medicine. NICE guidance sets who the NHS will fund it for, which is usually a narrower group. Private prescribers work to the licence and their own clinical judgement, which is why private eligibility is broader. Our guide to private vs NHS weight loss treatment compares the two routes.

NICE TA875: Wegovy for weight management

NICE published TA875 in March 2023. It is the main guidance for Wegovy as a weight-loss treatment on the NHS.

Who it covers

TA875 recommends semaglutide, alongside a reduced-calorie diet and increased physical activity, for adults who have:

• a BMI of at least 35, plus at least one weight-related condition, or
• a BMI of 30 to 34.9, if they meet the criteria for referral to a specialist weight management service under NICE's obesity guidance.

Weight-related conditions include type 2 diabetes, high blood pressure, abnormal blood fats (dyslipidaemia), obstructive sleep apnoea and cardiovascular disease, among others.

Lower thresholds for some ethnic groups

NICE recognises that people from some ethnic backgrounds develop weight-related health problems at a lower BMI. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, the BMI thresholds are usually reduced by 2.5 kg/m². Our guide to lower BMI thresholds by ethnicity explains the reasoning and the evidence behind it.

Where it is prescribed

TA875 specifies that semaglutide should be used within a specialist weight management service that provides multidisciplinary care. These are sometimes called "tier 3" or "tier 4" services. They typically include doctors, specialist nurses, dietitians, psychologists and physical activity specialists. The medicine is one part of a broader programme rather than a standalone prescription.

The two-year limit

TA875 recommends semaglutide for a maximum of two years. This reflected the length of the trials and the cost-effectiveness modelling available at the time. It is not a safety limit, and the trial evidence shows that weight tends to return after stopping (see our Wegovy maintenance guide). NICE has begun a review of TA875, combining it with a new appraisal. Until that review concludes, the two-year limit remains part of the published guidance. Check the NICE website for the current position.

The table at a glance

This summary is simplified. The full NICE documents contain further detail, and local commissioning arrangements decide how each recommendation is delivered.

NICE TA1152: Wegovy for heart health

In May 2026, NICE published TA1152, recommending semaglutide (up to a 2.4mg weekly maintenance dose), alongside a reduced-calorie diet and increased physical activity, as an option to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of at least 27.

Established cardiovascular disease in this context means a previous heart attack, a previous ischaemic or haemorrhagic stroke, or symptomatic peripheral arterial disease. This reflects the population studied in the SELECT trial, which found a 20% relative reduction in major cardiovascular events with semaglutide compared with placebo over an average follow-up of more than three years. Our guide to Wegovy and heart health explains SELECT in detail.

Some key points about TA1152:

• It is a different indication from weight management. People are being treated primarily to reduce cardiovascular risk, with weight loss as one part of that.
• The guidance does not specify a setting, which means integrated care boards (ICBs) can decide whether it is delivered in primary care, cardiology services or elsewhere.
• NICE estimated that more than a million people in England could be eligible, so implementation is likely to be gradual and uneven, at least at first.
• Commissioners in England are normally required to fund NICE-recommended treatments within 90 days of final guidance, but that does not always mean immediate access in every area.

If you have had a heart attack, stroke or symptomatic peripheral arterial disease and have a BMI of 27 or more, it is reasonable to ask your GP or cardiology team whether semaglutide might be appropriate for you and how it is being provided locally.

How referral to a specialist weight management service works

Step 1: talk to your GP

Your GP is usually the starting point. They will typically check your weight, height and BMI, review your medical history and current medicines, check for conditions such as diabetes, high blood pressure and sleep apnoea, and discuss what you have tried so far. They may arrange blood tests.

Step 2: referral

If you meet local criteria, your GP can refer you to a specialist weight management service. Referral criteria are set locally and may be stricter than the NICE thresholds because of capacity. Some services require you to have tried a lower-tier programme (such as a community weight management group or the NHS Digital Weight Management Programme) first.

Step 3: assessment

The specialist team will carry out a fuller assessment, which may include dietetic, psychological and medical reviews. Medication is only one possible outcome. Some people are offered a structured programme without medication, others may be considered for bariatric surgery, and some will be offered a GLP-1 medicine.

Step 4: treatment and follow-up

If semaglutide is prescribed, you will usually have regular follow-up to monitor weight, side effects and progress, and to provide dietary and behavioural support. The Wegovy SmPC advises reviewing treatment if a person has not lost at least 5% of their initial body weight after six months on the treatment dose.

Why access is limited

Even where people meet NICE criteria, many find it difficult to get NHS Wegovy. The main reasons are:

• Capacity. Specialist weight management services were not designed for the number of people now eligible. In many areas there are long waits or no service at all.
• Local commissioning. ICBs decide how to fund and organise services, so availability varies by postcode.
• Supply. Supply of semaglutide was constrained for periods after launch. Supply has improved, but local stock issues can still occur.
• Competing priorities. Services must balance demand from people seeking medicines, surgery and non-drug support.

This is one reason many people look at private prescribing. If you are considering that route, our guide to how to choose an online pharmacy for weight loss explains what to check, and our provider comparison sets out how services differ. Costs vary by provider and dose; our prices page explains what affects them.

How Wegovy compares with Mounjaro on the NHS

Tirzepatide (Mounjaro) has its own NHS route under NICE TA1026 (December 2024). Unlike TA875, NICE agreed a funding variation that allows a phased rollout over several years, including in primary care. NHS England's interim commissioning guidance set out that, from 23 June 2025, ICBs should fund tirzepatide in primary care for prioritised groups, starting with adults with a BMI of 40 or more and at least four of five qualifying conditions (type 2 diabetes, high blood pressure, heart disease, obstructive sleep apnoea and abnormal blood fats). Later cohorts extend to lower BMI bands. Prescribing must be accompanied by "wraparound care" that includes, as a minimum, dietary and nutritional advice and access to behavioural support.

That means some people may be offered Mounjaro through their GP while Wegovy for weight management remains mainly a specialist-service medicine. Neither is automatically "better" for an individual. The SURMOUNT-5 trial found greater average weight loss with tirzepatide than with semaglutide, but semaglutide has the SELECT cardiovascular outcome data and the TA1152 recommendation. Our Mounjaro on the NHS guide explains the tirzepatide rollout in detail, and our Mounjaro vs Wegovy comparison looks at the differences.

What is not covered by NHS guidance (at the time of writing)

The 7.2mg dose

In January 2026 the MHRA authorised a higher maximum dose of 7.2mg weekly for adults with obesity (BMI of 30 or more). NICE will need to assess it before it is routinely available on the NHS. At the time of writing, NHS guidance covers doses up to 2.4mg.

Wegovy tablets

The MHRA authorised Wegovy tablets (oral semaglutide 25mg) for weight management in June 2026. NICE had not recommended them for NHS use at the time of writing. See our oral semaglutide guide for details.

Ozempic

Ozempic contains semaglutide but is licensed only for type 2 diabetes. It is not an NHS weight-loss treatment. Our Ozempic vs Wegovy guide explains the difference.

Other NHS support while you wait

A GLP-1 medicine is not the only form of NHS help for weight management, and services generally see medication as one part of a wider plan. Depending on where you live and your health, options may include:

• Local community weight management programmes, sometimes called tier 2 services, which offer group or one-to-one support with diet, activity and behaviour change, often for around 12 weeks.
• The NHS Digital Weight Management Programme, a free online programme in England for adults living with obesity who also have diabetes, high blood pressure or both. Referral is usually through a GP practice or community pharmacy, and eligibility criteria are set nationally.
• The NHS Diabetes Prevention Programme, for people identified as being at high risk of type 2 diabetes.
• Treatment of related conditions, such as optimising blood pressure, cholesterol and diabetes treatment, and assessment for obstructive sleep apnoea.
• Bariatric surgery, for people who meet the criteria, through specialist services. Our guide to GLP-1 medication vs bariatric surgery compares the two.

These programmes can be worthwhile in their own right. Some specialist services also ask whether you have engaged with lower-tier support before referral, so it may help your case to take part.

What happens at the end of a two-year course?

If you are receiving semaglutide under TA875, the two-year limit means your team should plan with you for what comes next. That plan may include continued dietetic and psychological support, monitoring of weight and related conditions, and a discussion of other options if weight starts to return. Trial evidence shows that, on average, a substantial part of the weight lost on semaglutide returns within a year of stopping. Our Wegovy maintenance guide looks at that evidence and at practical steps that can help.

Some people choose to continue privately after an NHS course ends. If you are considering this, tell your NHS team, make sure the private prescriber has your full treatment history (including your current dose), and avoid gaps where possible, because a long break usually means restarting at a lower dose. Because NICE is reviewing TA875, the two-year rule may change; your team will be able to tell you the current position.

Scotland, Wales and Northern Ireland

The details above mainly describe England. Elsewhere in the UK:

• Scotland: the Scottish Medicines Consortium (SMC) assesses new medicines separately from NICE, and NHS boards decide how to deliver services locally. In October 2023 the SMC accepted semaglutide (Wegovy) for restricted use within NHSScotland for weight management: for people with a BMI of at least 30 and at least one weight-related condition, treated within a specialist weight management service, with a lower BMI cut-off potentially appropriate for some minority ethnic groups. Local access arrangements still differ between boards.
• Wales: Wales generally follows NICE technology appraisals, with health boards responsible for delivery.
• Northern Ireland: NICE guidance is reviewed for applicability by the Department of Health in Northern Ireland, and local services decide how it is implemented.

If you live outside England, your GP or local health board is the most reliable source of up-to-date information on referral routes and waiting times.

Common misunderstandings about NHS Wegovy

"My BMI qualifies me, so my GP must prescribe it." Meeting the NICE thresholds makes you potentially eligible, but TA875 recommends Wegovy within specialist services, and local referral criteria and capacity apply. A GP is not normally expected to start Wegovy for weight management on their own.

"The two-year limit is because it becomes unsafe." The limit reflected the evidence and cost modelling at the time. It is not a safety cut-off.

"If I get Mounjaro from my GP, I can get Wegovy too." You should not take two GLP-1 medicines at the same time. If you are offered one, the other would not be added.

"Wegovy tablets are available on the NHS now they are licensed." A licence is not the same as NHS funding. At the time of writing, NICE had not recommended them.

Questions to ask your GP

If you are interested in Wegovy on the NHS, these questions can help you get clear information:

• Do I meet the criteria for referral to a specialist weight management service here?
• Is there a local service, and roughly how long is the wait?
• Do I need to complete another programme first?
• Would I be eligible for semaglutide under the cardiovascular guidance (TA1152)?
• Would tirzepatide under TA1026 be an option for me, and when might my cohort be eligible?
• Are there other treatments or support I should consider while I wait?

You can also use our BMI calculator and eligibility checker to understand where you stand. They are informational tools only and do not replace a clinical assessment.

If you are already on NHS Wegovy

If you are already receiving semaglutide through a specialist service:

• Attend follow-up appointments, as continued supply usually depends on them.
• Ask your team what will happen at the end of the two-year period, if it applies to you.
• Report side effects promptly, including through the MHRA Yellow Card scheme.
• Do not combine NHS and private prescriptions for GLP-1 medicines without telling both prescribers. Taking two GLP-1 medicines together is not recommended.

When to speak to a professional

Speak to your GP if:

• You think you may meet the criteria for Wegovy under TA875 or TA1152 and want to discuss referral.
• You have a weight-related condition, such as type 2 diabetes, high blood pressure or sleep apnoea, that is getting worse.
• You are already on Wegovy and approaching the end of a time-limited course.
• You are pregnant, planning pregnancy or breastfeeding, as Wegovy is not suitable at these times.

Seek urgent medical help (NHS 111, or 999 in an emergency) if you are taking Wegovy and develop:

• Severe, persistent abdominal pain, sometimes spreading to the back, with or without vomiting (possible pancreatitis).
• Pain in the upper right abdomen with fever or yellowing of the skin or eyes (possible gallbladder problems).
• Persistent vomiting or diarrhoea with signs of dehydration.
• Swelling of the face, lips or throat, or difficulty breathing.
• Sudden loss of vision or blurred vision in one eye.

For more on Wegovy, visit our Wegovy hub. Whether Wegovy is suitable for you, and through which route, is a decision for a qualified prescriber who has assessed your health.